Biotech week ahead, March 7

 Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.

Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off.

NuCana plc. (NASDAQ: NCNA) was among the worst decliners of the week, with the stock reacting to the stalling of the company's Phase 3 biliary tract cancer study.

SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company's SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study.

FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT) and Gilead Sciences, Inc. (NASDAQ: GILD) failing to get their investigational drugs across the finish line. On the other hand, Legend Biotech Corporation (NASDAQ: LEGN) and CTI BioPharma Corp. (NASDAQ: CTIC) received approvals for their treatments for multiple myeloma and myelofibrosis, respectively.

Here are the key catalysts that can impact trading in biopharma stocks in the unfolding week:

Conferences

Cowen 42nd Annual Health Care Conference (virtual): March 7-9

Earnings

The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.

Monday

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) (before the market open)

DURECT Corporation (NASDAQ: DRRX) (after the close)

Tuesday

Neuronetics, Inc. (NASDAQ: STIM) (before the market open)

InspireMD, Inc. (NASDAQ: NSPR) (before the market open)

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) (before the market open)

Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)

Aquestive Therapeutics, Inc. (NASDAQ: AQST) (after the close)

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (after the close)

Anika Therapeutics, Inc. (NASDAQ: ANIK) (after the close)

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) (after the close)

Evoke Pharma, Inc. (NASDAQ: EVOK) (after the close)

Wednesday

Selecta Biosciences, Inc. (NASDAQ: SELB) (before the market open)

Assertio Holdings, Inc. (NASDAQ: ASRT) (before the market open)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) (after the close)

Histogen Inc. (NASDAQ: HSTO) (after the close)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) (after the close)

Thursday

Tecogen Inc. (NASDAQ: TGEN) (before the market open)

TherapeuticsMD, Inc. (NASDAQ: TXMD) (before the market open)

Lineage Cell Therapeutics, Inc. (NYSE: LCTX) (before the market open)

Genocea Biosciences, Inc. (NASDAQ: GNCA) (before the market open)

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) (before the market open)

Autolus Therapeutics plc (NASDAQ: AUTL) (before the market open)

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (after the close)

Achieve Life Sciences, Inc. (NASDAQ: ACHV) (after the close)

Clearside Biomedical, Inc. (NASDAQ: CLSD) (after the close)

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) (after the close)

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) (after the close)

OncoCyte Corporation (NASDAQ: OCX) (after the close)

Geron Corporation (NASDAQ: GERN) (after the close)

Lantern Pharma Inc. (NASDAQ: LTRN) (after the close)

Zumiez Inc. (NASDAQ: ZUMZ) (after the close)

Viridian Therapeutics, Inc. (NASDAQ: VRDN) (after the close)

Neovasc Inc. (NASDAQ: NVCN) (after the close)

Regulus Therapeutics Inc. (NASDAQ: RGLS) (after the close)

Lumos Pharma, Inc. (NASDAQ: LUMO) (after the close)

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (after the close)

Friday

PLx Pharma Inc. (NASDAQ: PLXP) (before the market open)

IPOs

IPO Quiet Period Expiry

TC Biopharm (Holdings) Plc (NASDAQ: TCBP)

https://www.msn.com/en-us/money/news/the-week-ahead-in-biotech-march-6-12-quiet-week-on-tap-with-earnings-season-reaching-it-final-leg/ar-AAUGXfV